دورية أكاديمية
A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2.
| العنوان: | A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2. |
|---|---|
| المؤلفون: | Tsegay KB; Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, United States., Adeyemi CM; St. Louis University School of Medicine, Department of Pharmacology and Physiology, St. Louis, MO, United States., Gniffke EP; Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, United States., Sather DN; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States.; Department of Pediatrics, University of Washington, Seattle, WA, United States., Walker JK; St. Louis University School of Medicine, Department of Pharmacology and Physiology, St. Louis, MO, United States.; Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University St. Louis, Seattle, WA, United States., Smith SEP; Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, United States.; Department of Pediatrics, University of Washington, Seattle, WA, United States.; Graduate Program in Neuroscience, University of Washington, Seattle, WA, United States. |
| المصدر: | Frontiers in pharmacology [Front Pharmacol] 2021 Jun 14; Vol. 12, pp. 685308. Date of Electronic Publication: 2021 Jun 14 (Print Publication: 2021). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Media] |
| مستخلص: | Repurposed drugs that block the interaction between the SARS-CoV-2 spike protein and its receptor ACE2 could offer a rapid route to novel COVID-19 treatments or prophylactics. Here, we screened 2,701 compounds from a commercial library of drugs approved by international regulatory agencies for their ability to inhibit the binding of recombinant, trimeric SARS-CoV-2 spike protein to recombinant human ACE2. We identified 56 compounds that inhibited binding in a concentration-dependent manner, measured the IC Competing Interests: Seattle Children’s Research Institute has filed a provisional patent on the use of the inhibition assay for drug screening described herein. (Copyright © 2021 Tsegay, Adeyemi, Gniffke, Sather, Walker and Smith.) |
| التعليقات: | Update of: bioRxiv. 2021 Apr 08;:. (PMID: 33851160) |
| References: | Med Oncol. 2018 Feb 13;35(3):38. (PMID: 29442179) J Vet Pharmacol Ther. 2002 Aug;25(4):265-72. (PMID: 12213114) Nucleic Acids Res. 2000 Jan 1;28(1):235-42. (PMID: 10592235) J Infect Dis. 2020 Nov 13;222(12):1965-1973. (PMID: 32798222) Front Pharmacol. 2021 Jan 13;11:600372. (PMID: 33519460) J King Saud Univ Sci. 2021 Mar;33(2):101344. (PMID: 33531790) Nucleic Acids Res. 2007 Jul;35(Web Server issue):W407-10. (PMID: 17517781) Nat Commun. 2020 Dec 9;11(1):6317. (PMID: 33298944) Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303. (PMID: 29788355) Biophys J. 2021 Jul 20;120(14):2793-2804. (PMID: 34214539) Psychoneuroendocrinology. 2018 Jan;87:9-19. (PMID: 29032324) Contraception. 1980 Apr;21(4):415-24. (PMID: 7389356) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. (PMID: 24841273) Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877) Adv Ther (Weinh). 2021 May;4(5):2000224. (PMID: 33786369) N Engl J Med. 2021 Feb 11;384(6):497-511. (PMID: 33264556) BMJ. 2020 May 14;369:m1849. (PMID: 32409561) Antimicrob Agents Chemother. 2018 Jun 26;62(7):. (PMID: 29712664) Cancer Chemother Pharmacol. 2003 Aug;52(2):159-66. (PMID: 12759775) N Engl J Med. 2020 May 7;382(19):1787-1799. (PMID: 32187464) J Clin Pharmacol. 2018 Dec;58(12):1533-1540. (PMID: 30179260) ACS Pharmacol Transl Sci. 2020 Nov 17;3(6):1352-1360. (PMID: 33330843) Physiol Genomics. 2020 Sep 1;52(9):401-407. (PMID: 32809918) Acta Oncol. 2016;55(2):140-8. (PMID: 26161618) Vet Parasitol. 1999 Feb 1;81(1):47-55. (PMID: 9950328) Inform Med Unlocked. 2020;21:100451. (PMID: 33083517) Chin Med J (Engl). 2020 May 5;133(9):1051-1056. (PMID: 32149769) Biochem Biophys Rep. 2021 Jul;26:100982. (PMID: 33817352) Curr Protoc Bioinformatics. 2016 Mar 24;53:1.29.1-1.29.15. (PMID: 27010333) JAMA. 2020 Jul 14;324(2):131-132. (PMID: 32539093) Methods Enzymol. 1997;277:396-404. (PMID: 9379925) J Biomol Struct Dyn. 2022 Mar;40(4):1597-1606. (PMID: 33030105) Nat Chem. 2011 Aug 21;3(9):725-31. (PMID: 21860463) Basic Clin Pharmacol Toxicol. 2021 Apr;128(4):621-624. (PMID: 33232578) BMC Med. 2020 Nov 25;18(1):369. (PMID: 33234138) Neuropeptides. 2012 Oct;46(5):211-5. (PMID: 22884888) N Engl J Med. 2020 Nov 5;383(19):1813-1826. (PMID: 32445440) Eur J Pharm Sci. 2021 May 1;160:105771. (PMID: 33617948) ACS Infect Dis. 2020 Sep 11;6(9):2304-2318. (PMID: 32687696) Cell. 2020 May 14;181(4):905-913.e7. (PMID: 32333836) Cancer Chemother Pharmacol. 1998;41(4):257-67. (PMID: 9488594) Obstet Gynecol. 1980 Dec;56(6):701-4. (PMID: 7443113) World J Surg Oncol. 2013 May 30;11:120. (PMID: 23721525) |
| معلومات مُعتمدة: | R01 AI140951 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: COVID-19; IP-FCM; drug screen; inhibition assay; repurposed |
| تواريخ الأحداث: | Date Created: 20210701 Latest Revision: 20231107 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8236845 |
| DOI: | 10.3389/fphar.2021.685308 |
| PMID: | 34194331 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2021.685308 |